Company intelligence / Profile preview

Scientific Development

Ownership: Private
Development stage: Other

Overview

Scientific Development was a biotechnology company primarily focused on the development of metabolic disease treatments. The company's lead research efforts were centered on oral small molecule agonists of the glucagon-like peptide 1 receptor (GLP-1R) for the treatment of type 2 diabetes and obesity. Despite early-stage research into these high-demand therapeutic areas, the company is no longer active and has ceased operations. Its intellectual property and research findings were historically relevant in the competitive landscape of oral GLP-1 therapies.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Scientific Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scientific Development.

Explore the full profile